Humacyte (HUMA) Stock Price, News & Analysis

Company Overview

Humacyte, Inc. is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation. Humacyte is also exploring additional indications, including peripheral and coronary artery bypass and central venous access, with the goal of addressing significant unmet medical needs in cardiovascular surgery and interventional medicine. Research and development efforts are supported by Good Manufacturing Practice (GMP) facilities in the United States, enabling scale-up from laboratory to commercial production.

Founded in 2004 by Dr. Scott B. Rhodes at Duke University, Humacyte is headquartered in Durham, North Carolina, with ongoing clinical programs and partnerships extending into Europe and North America. The company is led by a management team with experience spanning cell therapy, regenerative medicine and vascular surgery. Humacyte continues to work alongside clinical investigators and strategic collaborators to advance its HAV technology toward regulatory approval and broad clinical adoption.

Key Stats

• Today's Range: $1.45 to $1.55
• 50-Day Range: $1.41 to $2.73
• 52-Week Range: $1.15 to $6.77
• Volume: 2.43 million shs
• Average Volume: 3.92 million shs
• Market Capitalization: $242.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.75
• Consensus Rating: Moderate Buy

Humacyte Stock Analysis - MarketRank™

Humacyte scored higher than 63% of companies evaluated by MarketBeat, and ranked 412th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Humacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Humacyte has a consensus price target of $9.75, representing about 537.3% upside from its current price of $1.53.

Amount of Analyst Coverage

Humacyte has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Humacyte are expected to grow in the coming year, from ($1.27) to ($0.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Humacyte is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Humacyte is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.62% of the float of Humacyte has been sold short.

Short Interest Ratio / Days to Cover

Humacyte has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Humacyte has recently decreased by 1.90%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Humacyte does not currently pay a dividend.

Dividend Growth

Humacyte does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

25.62% of the float of Humacyte has been sold short.

Short Interest Ratio / Days to Cover

Humacyte has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Humacyte has recently decreased by 1.90%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.53

News Sentiment

Humacyte has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Humacyte this week, compared to 7 articles on an average week.

Search Interest

Only 2 people have searched for HUMA on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.

MarketBeat Follows

3 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Humacyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,466,382.00 in company stock.

Percentage Held by Insiders

Only 5.10% of the stock of Humacyte is held by insiders.

Percentage Held by Institutions

44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HUMA Stock Analysis - Frequently Asked Questions

How have HUMA shares performed this year?

Humacyte's stock was trading at $5.05 at the start of the year. Since then, HUMA stock has decreased by 69.7% and is now trading at $1.53.

How were Humacyte's earnings last quarter?

Humacyte, Inc. (NASDAQ:HUMA) released its earnings results on Monday, August, 11th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.09. The company earned $0.30 million during the quarter, compared to analysts' expectations of $0.94 million.
Read the conference call transcript.

Who are Humacyte's major shareholders?

Humacyte's top institutional shareholders include CenterBook Partners LP (2.21%), Geode Capital Management LLC (1.90%), Marshall Wace LLP (1.70%) and Bank of America Corp DE (0.32%). Insiders that own company stock include Gordon M Binder, Kathleen Sebelius, Dale A Sander, William John Scheessele, Michael T Constantino, Shamik J Parikh, Heather Ledbetter Prichard, Laura E Niklason and Brady W Dougan.
View institutional ownership trends.

How do I buy shares of Humacyte?

Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Humacyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Humacyte investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Intel (INTC), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HUMA
• CIK: 1818382
• Web: www.constellationalpha.com
• Phone: 919-313-9633
• Fax: N/A
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Humacyte: $9.75
• High Price Target: $25.00
• Low Price Target: $3.00
• Potential Upside/Downside: +561.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$148.70 million
• Net Margins: N/A
• Pretax Margin: -7,171.27%
• Return on Equity: N/A
• Return on Assets: -78.26%

Debt

• Debt-to-Equity Ratio: 2.97
• Current Ratio: 2.45
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: $1.57 million
• Price / Sales: 148.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.41) per share
• Price / Book: -3.60

Miscellaneous

• Outstanding Shares: 158,370,000
• Free Float: 150,295,000
• Market Cap: $233.60 million
• Optionable: Optionable
• Beta: 1.88